Solving doubts about L‐ornithine L‐aspartate for overt hepatic encephalopathy: Whom and how to treat
Piero Amodio, Javier Ampuero – 16 September 2017
Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient
Julien Vionnet, Manuel Pascual, Barbara Testoni, Christophe Combet, Sébastien Godat, Sandrine Vijgen, Vincent Aubert, Laura Rubbia‐Brandt, Fabien Zoulim, Darius Moradpour – 16 September 2017 – Direct‐acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV‐HCV‐coinfected patients treated with DAAs.
Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient
Julien Vionnet, Manuel Pascual, Barbara Testoni, Christophe Combet, Sébastien Godat, Sandrine Vijgen, Vincent Aubert, Laura Rubbia‐Brandt, Fabien Zoulim, Darius Moradpour – 16 September 2017 – Direct‐acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV‐HCV‐coinfected patients treated with DAAs.
Reply
Lisa B. VanWagner, Hongyan Ning, Maureen Whitsett, Josh Levitsky, Sarah Uttal, John T. Wilkins, Michael M. Abecassis, Daniela P. Ladner, Anton I. Skaro, Donald M. Lloyd‐Jones – 16 September 2017
Developing a prediction model for cardiovascular risk after orthotopic liver transplantation
Fu‐Shan Xue, Ya‐Yang Liu, Gui‐Zhen Yang – 16 September 2017
Radiosensitization by inhibiting DNA repair: Turning the spotlight on homologous recombination
Bhanu P. Venkatesulu, Sunil Krishnan – 16 September 2017
Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome‐wide association study
Mei‐Hsuan Lee, Yu‐Han Huang, Hsuan‐Yu Chen, Seik‐Soon Khor, Ya‐Hsuan Chang, Yu‐Ju Lin, Chin‐Lan Jen, Sheng‐Nan Lu, Hwai‐I Yang, Nao Nishida, Masaya Sugiyama, Masashi Mizokami, Yong Yuan, Gibert L'Italien, Katsushi Tokunaga, Chien‐Jen Chen, for the REVEAL‐HCV Cohort Study Group – 16 September 2017 – We conducted a genome‐wide association study to discover genetic variants associated with hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC). We genotyped 502 HCC cases and 749 non‐HCC controls using the Axiom‐CHB genome‐wide array.
Viral upper respiratory infection at pediatric liver transplantation is associated with hepatic artery thrombosis
Jordan A. Kohler, Flor M. Munoz, John A. Goss, Tamir A. Miloh – 15 September 2017
Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma
Oriana Lo Re, Caterina Fusilli, Francesca Rappa, Matthias Van Haele, Julien Douet, Jana Pindjakova, Sura Wanessa Rocha, Illar Pata, Barbora Valčíková, Stjepan Uldrijan, Raymond S. Yeung, Christina Alves Peixoto, Tania Roskams, Marcus Buschbeck, Tommaso Mazza, Manlio Vinciguerra – 15 September 2017 – Hepatocellular carcinomas (HCC) contain a subpopulation of cancer stem cells (CSCs), which exhibit stem cell–like features and are responsible for tumor relapse, metastasis, and chemoresistance.
LiverLearning®: 2017 Webinar: Chronic Hepatitis B and Pregnancy: Management and Prevention of Vertical Transmission
The management of women of child-bearing age and pregnant women with chronic hepatitis B requires special consideration due to the potential effects of antiviral therapy on unborn fetus and potential for hepatitis flares for pregnant and postpartum women. While universal maternal screening programs and immunoprophylaxis to newborns have greatly reduced mother-to-child-transmission (MTCT), immunoprophylaxis can fail in up to 30% of infants, especially in mothers with high HBV DNA levels and positive HBeAg.